In vivo glycosylation of mucin tandem repeats

被引:36
作者
Silverman, HS
Parry, S
Sutton-Smith, M
Burdick, MD
McDermott, K
Reid, CJ
Batra, SK
Morris, HR
Hollingsworth, MA
Dell, A
Harris, A [1 ]
机构
[1] Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England
[2] Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England
[3] Univ Nebraska, Med Ctr, Eppley Inst, Omaha, NE 68198 USA
[4] Univ Nebraska, Med Ctr, Dept Biochem, Omaha, NE 68198 USA
关键词
glycosylation; mucin; tandem repeat; in vivo;
D O I
10.1093/glycob/11.6.459
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The biochemical and biophysical properties of mucins are largely determined by extensive O-glycosylation of serine- and threonine-rich tandem repeat (TR) domains. In a number of human diseases aberrant O-glycosylation is associated with variations in the properties of the cell surface-associated and secreted mucins, To evaluate in vivo the O-glycosylation of mucin TR domains, we generated recombinant chimeric mucins with TR sequences from MUC2, MUC4 MUC5AC, or MUC5B, which were substituted for the native TRs of epitope-tagged MUC1 protein (MUC1F), These hybrid mucins were extensively O-glycosylated and showed the expected association with the cell surface and release into culture media. The presence of different TR domains within the chimeric mucins appears to have limited influence on their posttranslational processing. Alterations in glycosylation were detailed by fast atom bombardment mass spectrometry and reactivity with antibodies against particular blood-group and tumor-associated carbohydrate antigens, Future applications of these chimeras will include investigations of mucin posttranslational modification in the context of disease.
引用
收藏
页码:459 / 471
页数:13
相关论文
共 49 条
[1]  
ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8
[2]  
BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537
[3]   Expression of core 2 β-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes [J].
Beum, PV ;
Singh, J ;
Burdick, M ;
Hollingsworth, MA ;
Cheng, PW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (35) :24641-24648
[4]  
Boat T, 1989, CYSTIC FIBROSIS META, P2649
[5]   THE PRODUCT OF THE HUMAN MUC1 GENE WHEN SECRETED BY MOUSE CELLS TRANSFECTED WITH THE FULL-LENGTH CDNA LACKS THE CYTOPLASMIC TAIL [J].
BOSHELL, M ;
LALANI, EN ;
PEMBERTON, L ;
BURCHELL, J ;
GENDLER, S ;
TAYLORPAPADIMITRIOU, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 185 (01) :1-8
[6]   MECHANISMS UNDERLYING ABERRANT GLYCOSYLATION OF MUC1 MUCIN IN BREAST-CANCER CELLS [J].
BROCKHAUSEN, I ;
YANG, JM ;
BURCHELL, J ;
WHITEHOUSE, C ;
TAYLORPAPADIMITRIOU, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 233 (02) :607-617
[7]   Oligosaccharides expressed an MUC1 produced by pancreatic and colon tumor cell lines [J].
Burdick, MD ;
Harris, A ;
Reid, CJ ;
Iwamura, T ;
Hollingsworth, MA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (39) :24198-24202
[8]   ALTERED CARBOHYDRATE-COMPOSITION OF SALIVARY MUCINS FROM PATIENTS WITH CYSTIC-FIBROSIS AND THE ADHESION OF PSEUDOMONAS-AERUGINOSA [J].
CARNOY, C ;
RAMPHAL, R ;
SCHARFMAN, A ;
LOGUIDICE, JM ;
HOUDRET, N ;
KLEIN, A ;
GALABERT, C ;
LAMBLIN, G ;
ROUSSEL, P .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1993, 9 (03) :323-334
[9]   INCREASED SULFATION OF GLYCOCONJUGATES BY CULTURED NASAL EPITHELIAL-CELLS FROM PATIENTS WITH CYSTIC-FIBROSIS [J].
CHENG, PW ;
BOAT, TF ;
CRANFILL, K ;
YANKASKAS, JR ;
BOUCHER, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (01) :68-72
[10]   MUCIN CHANGES IN ILEOANAL POUCHES MONITORED BY METABOLIC LABELING AND HISTOCHEMISTRY [J].
CORFIELD, AP ;
WARREN, BF ;
BARTOLO, DCC ;
WAGNER, SA ;
CLAMP, JR .
BRITISH JOURNAL OF SURGERY, 1992, 79 (11) :1209-1212